SCHEMBL20166468

SCHEMBL20166468

O=C(O)c1ccc2c(-c3ccccc3Cl)n[nH]c2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 7/20 0.58
MAPK8 P45983 4/20 0.58
MAPK10 P53779 4/20 0.58
MAPK14 Q16539 4/20 0.58
MAPK1 P28482 3/20 0.52
MAPK6 Q16659 3/20 0.52
MAPKAPK3 Q16644 1/20 0.52
ITK Q08881 1/20 0.52
HDAC6 Q9UBN7 1/20 0.48
MAPKAPK5 Q8IW41 1/20 0.48
ALPL P05186 1/20 0.48
PAK1 Q13153 1/20 0.47
CHEK1 O14757 2/20 0.44
PRKAB2 O43741 2/20 0.44
PRKAG1 P54619 2/20 0.44
PRKAA2 P54646 2/20 0.44
PRKAA1 Q13131 2/20 0.44
PRKAG3 Q9UGI9 2/20 0.44
PRKAG2 Q9UGJ0 2/20 0.44
PRKAB1 Q9Y478 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21536862 0.88 CHEK1 (0.58) MAP2K4MAPK8MAPK10MAPK14MAPK1
SCHEMBL21536779 0.85 PAK1 (0.61) MAP2K4MAPK8MAPK10MAPK14MAPK1
SCHEMBL20167111 0.85 MAP2K4 (0.61) MAP2K4MAPK8MAPK10MAPK14MAPK1
SCHEMBL20167107 0.78 DGAT2 (0.53) MAPK8MAPK10MAPK14CHEK1
SCHEMBL20167110 0.78 DGAT2 (0.64) CHEK1GSK3B
SCHEMBL3960972 0.77 AXL (0.54) MAP2K4MAPK8MAPK10MAPK14PAK1
SCHEMBL30364178 0.76 IDO1 (0.60) MAP2K4MAPK10MAPK1MAPK6MAPKAPK3
SCHEMBL3966282 0.75 NPBWR1 (0.55) MAPK8MAPK10MAPK14PAK1
SCHEMBL9907662 0.74 HTR5A (0.56)
SCHEMBL5638533 0.74 ITK (0.81) MAP2K4MAPK1MAPK6MAPKAPK3ITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190330239-A1 INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 MERCK SHARP & DOHME CORP. (US) 2019-10-31 US disclosed
US-20190330239-A1 INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 MERCK SHARP & DOHME CORP. (US) 2019-10-31 US disclosed
EP-3541374-A1 INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 Merck Sharp & Dohme Corp. (US) 2019-09-25 EP disclosed
WO-2018093696-A1 INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 MERCK SHARP & DOHME CORP. (US) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190330239-A1 INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 DGAT2, DGAT1, MOGAT2 MAP2K4 3100/4885MAPK8 3400/4885MAPK10 3229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.